Calroy Health Sciences' Cartigenix HP, a joint health supplement with a proprietary blend called RestorCel, demonstrated measurable cartilage regeneration biomarkers in a 2025 placebo-controlled study. The research, involving over 1,700 participants across three studies, showed an average 67% reduction in pain and a 50% increase in walking distance within 90 days. This marks a significant advancement over traditional supplements like glucosamine and chondroitin, which lack consistent evidence for cartilage regeneration. Cartigenix HP offers clinicians and patients a scientifically backed option for structural joint support with noticeable improvements reported as early as 15 days.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
